Evidence map›Paper›PMID 42466917›Full record

ReviewBalkan medical journal2026

Bias and Fairness Across the Healthcare AI Lifecycle: A Clinician-Oriented Review.

Burak Kocak, Andrea Ponsiglione, Vien Ngoc Dang, Matthias Dietzel, Karim Lekadir, Renato Cuocolo

Abstract readReview
In one paragraph

Review in Balkan medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Burak KocakDepartment of Radiology, Başakşehir Çam and Sakura City Hospital, İstanbul, Türkiye.ORCID 0000-0002-7307-396X
Andrea PonsiglioneDepartment of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy.ORCID 0000-0002-0105-935X
Vien Ngoc DangArtificial Intelligence in Medicine Lab (BCN-AIM), Department of Mathematics and Computer Science, Universitat de Barcelona, Spain.ORCID 0000-0001-6271-818X
Matthias DietzelDepartment of Radiology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.ORCID 0000-0001-9248-1398
Karim LekadirArtificial Intelligence in Medicine Lab (BCN-AIM), Department of Mathematics and Computer Science, Universitat de Barcelona, Spain.ORCID 0000-0002-9456-1612
Renato CuocoloDepartment of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi, Italy.ORCID 0000-0002-1452-1574

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Artificial intelligence (AI) is increasingly being investigated and, in selected clinical settings, implemented to support diagnosis, triage, and workflow optimization. Although these systems have the potential to improve access, consistency, and efficiency, they may also reproduce or amplify health inequities when bias is introduced during development, evaluation, implementation, or postdeployment use. This clinician-oriented narrative review adopts a practical lifecycle approach to explain how algorithmic unfairness becomes clinically relevant, how clinicians can recognize it, and how institutions can mitigate its impact. We first outline the ethical, clinical, and mathematical dimensions of fairness. We then examine fairness risks and sources of bias across six stages of the healthcare AI lifecycle: problem formulation, data generation, model development, evaluation, implementation, and postdeployment monitoring and governance. Key mechanisms include biased proxy outcomes, unrepresentative or error-prone data and labels, model shortcut learning, hidden stratification, distribution shift, and human-AI interaction effects (e.g., automation bias and alert fatigue), all of which can create feedback loops and contribute to fairness drift over time. For each stage, we identify clinician-facing red flags and practical mitigation strategies, including defining clinically meaningful outcomes, using representative and well-documented datasets, conducting subgroup-stratified evaluations, performing external and prospective validation, justifying decision thresholds, implementing safeguards for human-AI interactions, and maintaining continuous postdeployment monitoring, including postmarket surveillance for regulated medical devices. Fairness cannot be ensured through a single metric, publication, regulatory clearance, or one-time validation. Instead, equitable healthcare AI requires transparent design, rigorous evaluation, local governance, and ongoing monitoring across diverse populations, clinical sites, devices, workflows, and time. Fairness should therefore be regarded as a continuous clinical and institutional responsibility rather than a downstream technical consideration.

Indexed as

Artificial IntelligenceBiasHumans

Identifiers

PMID42466917
PMCPMC13424742

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.